Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults

NCT00385255 PHASE3 COMPLETED Results posted

The current study will provide information for the use of Boostrix concomitantly with influenza vaccine in adults aged 19-64 years. This study will also provide safety and immunogenicity data in a cohort of adults aged greater than or equal to 65 years.

Details

Lead sponsor	GlaxoSmithKline
Phase	PHASE3
Status	COMPLETED
Enrolment	1726
Start date	Mon Oct 23 2006 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Feb 28 2007 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Acellular Pertussis
• Diphtheria
• Tetanus

Interventions

• Fluarix®
• Boostrix®

Countries

United States